genetic treatment Archives

aidsmeds

Gene Therapy Controls HIV Longer Than Four Months in Study

8 years ago NAPWHA Gene Therapy

Sangamo Biosciences’ efforts to develop genetic therapies for HIV have had some early success, with two of three participants in one cohort maintaining control of the virus for an extended period during which they were not taking standard antiretroviral (ARV) treatment. The biotech company is conducting a Phase I/II study, known as SB-728-1101, of its…

Research SpotlightRecent research in 100 words or less

Trust crucial to treatment interruption

At the Australasian HIV/AIDS Conference, Dr Gordon Campbell discussed participant motivations and experiences from an HIV cure clinical trial with treatment interruption (ATI). Dr Campbell interviewed participants from the TITAN study. All were satisfied with their experience and most felt well during the study. Trust in the clinical research team was crucial to their participation and peace-of-mind. They would participate in future ATI trials. Support for the HIV community was a primary reason for participation. Other motivations were an interest in cure science, curiosity about their immune system, and optimism for improved treatment or cure.
These findings show that ATI trials can proceed with HIV community support and will guide future ATI trials.

...

Find out about current studies

aidsmeds

Gene Therapy Controls HIV Longer Than Four Months in Study

Trust crucial to treatment interruption

Gene therapy advance in mice

New sequencing method shows many blood-derived HIV particles are defective

High CD4 count before HIV treatment contributes to smaller HIV reservoir on ART

Vitamin D3 affects the HIV reservoir in humans